U.S., May 2 -- ClinicalTrials.gov registry received information related to the study (NCT07562438) titled 'Prospective Clinical Trial of 177Lu-P17-088 in the Treatment of Metastatic Castration-Resistant Prostate Cancer' on April 27.
Brief Summary: PSMA is an ideal target for precision diagnosis and treatment of prostate cancer. P17-088 is a novel albumin-binding PSMA-targeted radioligand. This study aims to explore the safety and efficacy of 177Lu-labeled P17-088 for treating patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).
Study Start Date: April 29
Study Type: INTERVENTIONAL
Condition:
Prostate Cancer
Intervention:
DRUG: 177Lu-P17-088
administered intravenously once every 6-8 weeks (1 cycle) for...